Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Novel Treatment Options

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Serum and cerebrospinal fluid neurofilament levels predict longitudinal atrophy of the cervical spinal cord in progressive MS

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  2. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediction of natalizumab anti-drug antibodies persistency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Although immunosuppressants in the treatment of myasthenia have been available for several decades, population-based studies describing drug utilization in myasthenia patients are scarce. We aimed in this study to describe the treatment of myasthenia in Denmark in more recent years with emphasis on use of oral immunosuppressant agents. We identified a nationwide cohort of incident myasthenia patients in Denmark from 1996 to 2013 and tracked their use of drugs over the entire period using data from nationwide registers. Patients with myasthenia were classified according to utilization of specific immunosuppressants (e.g. prednisolone) as 'never user' or 'ever user'. We used Kaplan-Meier (K-M) and proportion of patients covered (PPC) curves to describe treatment onset and termination. We identified 928 patients (52% female) with incident myasthenia in the study period. Overall, 638 (69%) were treated with prednisolone and 506 (55%) with azathioprine. Treatment with prednisolone and azathioprine within 2 years of myasthenia diagnosis was initiated in 462 (56%) and 366 (45%). Only one of four myasthenia patients (n = 231) did not receive oral immunosuppressive treatment at any time in the study period. Prednisolone was stopped in most patients, whereas treatment with azathioprine was often continued throughout follow-up. In conclusion, we found that treatment of myasthenia in Denmark in recent years corresponded well to the expected clinical course of myasthenia and that most patients underwent long-term immunosuppression.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
Vol/bind123
Udgave nummer4
Sider (fra-til)486-493
Antal sider8
ISSN1742-7843
DOI
StatusUdgivet - okt. 2018

ID: 56324217